This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lapchak, P. A. Articles by Zivin, J. A. Search for Related Content PubMed PubMed Citation Articles by Lapchak, P. A. Articles by Zivin, J. A. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Acute Cerebral Hemorrhage Acute Cerebral Infarction Embolic stroke Thrombolysis

(Stroke. 2002;33:2279.)
© 2002 American Heart Association, Inc.

Original Contributions

Microplasmin: A Novel Thrombolytic That Improves Behavioral Outcome After Embolic Strokes in Rabbits

Paul A. Lapchak, PhD; Dalia M. Araujo, PhD; Steve Pakola, MD; Donghuan Song, MD; Jiandong Wei, MD Justin A. Zivin, MD, PhD

From the Department of Neuroscience, University of California at San Diego, La Jolla (P.A.L., D.S., J.W., J.A.Z.); VA San Diego Healthcare System, San Diego, Calif (P.A.L., D.M.A., D.S., J.W., J.A.Z.); Veterans Medical Research Foundation, San Diego, Calif (P.A.L., D.S., J.W., J.A.Z.); and ThromboGenics Ltd, Dublin, Ireland (S.P.).

Correspondence to Dr Paul A. Lapchak, Department of Neuroscience, University of California at San Diego, MTF 316, 9500 Gilman Dr, La Jolla, CA 92093-0624. E-mail plapchak{at}ucsd.edu

Background and Purpose— It has been proposed that the novel thrombolytic microplasmin may be useful in the treatment of ischemic stroke. In the present study the effects and safety profile of microplasmin were evaluated in 2 rabbit embolic stroke models that have been used successfully to develop tissue plasminogen activator (tPA) as the only Food and Drug Administration-approved treatment for stroke. The rabbit small clot embolic stroke model (RSCEM) and rabbit large clot embolic stroke model (RLCEM) were used to determine the potential neuroprotective properties and safety profile of microplasmin, respectively, after an embolic stroke.

Methods— Rabbits were embolized by injecting small blood clots (RSCEM) or large blood clots (RLCEM) into the cerebral circulation. For the RSCEM, 126 rabbits were included, with behavioral analysis conducted 24 hours later, allowing for determination of the effective stroke dose (ES₅₀) or clot amount (milligrams) that produces severe neurological deficits in 50% of rabbits. For RLCEM safety study analysis, 47 rabbits were included, with postmortem analyses consisting of assessment of hemorrhage and infarct rate and size. In test animals microplasmin was infused intravenously 60 minutes after embolization, whereas control rabbits were given infusions of the saline/Plasma-Lyte vehicle with all assessments performed in a blinded fashion.

Results— In the RSCEM, a drug is considered neuroprotective if it significantly increases the ES₅₀ compared with the vehicle-treated control group. The ES₅₀ of the vehicle-treated control group 24 hours after embolization was 1.36±0.42 mg (n=38). Microplasmin, infused starting 60 minutes after embolization, increased the ES₅₀ to 2.32±0.57 (n=21), 1.89±0.48 (n=21), 2.81±0.55 (n=22), and 1.89±0.28 mg (n=24) for the 1-, 2-, 4-, and 8-mg/kg doses, respectively. There was a statistically significant behavioral improvement in the 4-mg/kg dose arm (P=0.040). The microplasmin dose of microplasmin that was statistically significant (4 mg/kg) was subsequently determined to be safe in the RLCEM because it did not increase the incidence of hemorrhages (56%) compared with vehicle-treated rabbits (63%), nor did it significantly alter hemorrhage volume, infarct rate, or infarct volume.

Conclusions— The present study shows that microplasmin improves behavioral rating scores in the RSCEM when administered 60 minutes after embolization, at a dose that does not increase hemorrhages in the RLCEM. This is in contrast to tPA, which significantly enhances the hemorrhage rate in the RLCEM.

Key Words: ischemia • neuroprotection • reperfusion • thrombolytic therapy • tissue plasminogen activator • rabbits

This article has been cited by other articles:

				V. N.S. Thijs, A. Peeters, M. Vosko, F. Aichner, P. D. Schellinger, D. Schneider, T. Neumann-Haefelin, J. Rother, A. Davalos, N. Wahlgren, et al. Randomized, Placebo-Controlled, Dose-Ranging Clinical Trial of Intravenous Microplasmin in Patients With Acute Ischemic Stroke Stroke, December 1, 2009; 40(12): 3789 - 3795. [Abstract] [Full Text] [PDF]

				R.G. Nogueira, L.H. Schwamm, and J.A. Hirsch Endovascular Approaches to Acute Stroke, Part 1: Drugs, Devices, and Data AJNR Am. J. Neuroradiol., April 1, 2009; 30(4): 649 - 661. [Abstract] [Full Text] [PDF]

				F. Chen, Y. Suzuki, N. Nagai, X. Sun, H. Wang, J. Yu, G. Marchal, and Y. Ni Microplasmin and Tissue Plasminogen Activator: Comparison of Therapeutic Effects in Rat Stroke Model at Multiparametric MR Imaging Radiology, August 1, 2007; 244(2): 429 - 438. [Abstract] [Full Text] [PDF]

				C. A. Molina and J. L. Saver Extending Reperfusion Therapy for Acute Ischemic Stroke: Emerging Pharmacological, Mechanical, and Imaging Strategies Stroke, October 1, 2005; 36(10): 2311 - 2320. [Abstract] [Full Text] [PDF]

				T. Sakuma, M. Tanaka, A. Mizota, J. Inoue, and S. Pakola Safety of In Vivo Pharmacologic Vitreolysis with Recombinant Microplasmin in Rabbit Eyes Invest. Ophthalmol. Vis. Sci., September 1, 2005; 46(9): 3295 - 3299. [Abstract] [Full Text] [PDF]

				K. Tsuji, T. Aoki, E. Tejima, K. Arai, S.-R. Lee, D. N. Atochin, P. L. Huang, X. Wang, J. Montaner, and E. H. Lo Tissue Plasminogen Activator Promotes Matrix Metalloproteinase-9 Upregulation After Focal Cerebral Ischemia Stroke, September 1, 2005; 36(9): 1954 - 1959. [Abstract] [Full Text] [PDF]

				X. Wang, K. Tsuji, S.-R. Lee, M. Ning, K. L. Furie, A. M. Buchan, and E. H. Lo Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke Stroke, November 1, 2004; 35(11_suppl_1): 2726 - 2730. [Abstract] [Full Text] [PDF]

				Y. Suzuki, F. Chen, Y. Ni, G. Marchal, D. Collen, and N. Nagai Microplasmin Reduces Ischemic Brain Damage and Improves Neurological Function in a Rat Stroke Model Monitored With MRI Stroke, October 1, 2004; 35(10): 2402 - 2406. [Abstract] [Full Text] [PDF]

				P. A. Lapchak, J. Wei, and J. A. Zivin Transcranial Infrared Laser Therapy Improves Clinical Rating Scores After Embolic Strokes in Rabbits Stroke, August 1, 2004; 35(8): 1985 - 1988. [Abstract] [Full Text] [PDF]

				E. H. Lo, J. P. Broderick, and M. A. Moskowitz tPA and Proteolysis in the Neurovascular Unit Stroke, February 1, 2004; 35(2): 354 - 356. [Full Text] [PDF]

				P. A. Lapchak and J. A. Zivin Ebselen, a Seleno-Organic Antioxidant, Is Neuroprotective After Embolic Strokes in Rabbits: Synergism With Low-Dose Tissue Plasminogen Activator Stroke, August 1, 2003; 34(8): 2013 - 2018. [Abstract] [Full Text] [PDF]

				M. Fisher Recommendations for Advancing Development of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable 3 Stroke, June 1, 2003; 34(6): 1539 - 1546. [Abstract] [Full Text] [PDF]

				D. Stewart, M. Kong, V. Novokhatny, G. Jesmok, and V. J. Marder Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage Blood, April 15, 2003; 101(8): 3002 - 3007. [Abstract] [Full Text] [PDF]